Alembic Pharmaceuticals Wins USFDA Final Approval and 180-Day Exclusivity for Binimetinib Tablets
Approval covers 15 mg and 45 mg strengths for treatment of advanced melanoma and metastatic NSCLC with BRAF mutations
Alembic Pharmaceuticals has received USFDA final approval for its ANDA of Binimetinib Tablets, 15 mg and 45 mg, used in combination treatment for advanced melanoma and metastatic NSCLC. The company is eligible for 180 days of generic exclusivity in the US, with the market valued at US$ 282 million for the year ending September 2026.
Alembic Pharmaceuticals Limited
New Ventures
Alembic Pharmaceuticals Limited announced USFDA final approval of its Abbreviated New Drug Application for Binimetinib Tablets, 15 mg and 45 mg, granting the company 180 days of generic exclusivity in the US market.
The approved Binimetinib Tablets are therapeutically equivalent to the reference listed drug Mektovi Tablets from Array BioPharma Inc. Binimetinib is a kinase inhibitor used in combination with encorafenib for treating patients with unresectable or metastatic melanoma carrying BRAF V600E or V600K mutations, and metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
Alembic was among the first to submit an ANDA with paragraph IV certification for both dosages and is the sole first filer for the 45 mg strength, qualifying for 180 days of marketing exclusivity in the US.
The estimated market size for Binimetinib Tablets in the twelve months ending September 2026 is approximately US$ 282 million according to IQVIA data.
Alembic has received a cumulative total of 248 ANDA approvals from USFDA, comprising 230 final approvals and 18 tentative approvals, underscoring its significant presence in the generic pharmaceutical market.
Highlights
- USFDA final approval received for Binimetinib Tablets, 15 mg and 45 mg, under ANDA by Alembic Pharmaceuticals.
- Alembic eligible for 180 days of generic drug exclusivity in the US market for both dosages.
- Binimetinib indicated for combination use in advanced melanoma and metastatic NSCLC patients with specific BRAF mutations.
- Market size for Binimetinib Tablets estimated at US$ 282 million for 12 months ending September 2026.
- Alembic holds a portfolio of 248 ANDA approvals from the USFDA to date.
Key Data Snapshot
What happened
- Alembic Pharmaceuticals received USFDA final approval for its ANDA of Binimetinib Tablets in 15 mg and 45 mg strengths.
- The approval confirms therapeutic equivalence to the reference listed drug Mektovi Tablets from Array BioPharma Inc.
- Alembic was one of the first applicants for this drug with paragraph IV certification and sole first filer for the 45 mg dosage.
- This approval grants Alembic a 180-day generic exclusivity period for both strengths in the US market.
Key details
- Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for treating patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
- It is also approved for treatment of metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation in adults.
- Alembic's approval strengthens its generic oncology portfolio in the US.
Regulatory and governance context
- Alembic Pharmaceuticals has a longstanding record with the USFDA, having received a total of 248 ANDA approvals, including 230 final approvals.
- The company complies with all regulatory requirements for drug approval and manufacturing standards as per USFDA guidelines.
Highlights
- USFDA final approval received for Binimetinib Tablets, 15 mg and 45 mg, under ANDA by Alembic Pharmaceuticals.
- Alembic eligible for 180 days of generic drug exclusivity in the US market for both dosages.
- Binimetinib indicated for combination use in advanced melanoma and metastatic NSCLC patients with specific BRAF mutations.
- Market size for Binimetinib Tablets estimated at US$ 282 million for 12 months ending September 2026.
- Alembic holds a portfolio of 248 ANDA approvals from the USFDA to date.
Disclosures
- US Food & Drug Administration (USFDA) approval process
- Abbreviated New Drug Application (ANDA) regulations
- Paragraph IV Certification under Hatch-Waxman Act
More News on New Ventures
View allLatest corporate announcements and market updates in New Ventures.
Network People Services Technologies Limited Invests USD 1 Million in UAE Subsidiary NPST Global Solutions LLC Through Optionally Convertible Debentures
Network People Services Technologies Limited has invested USD 1,000,000 in its wholly owned subsidiary NPST Global Solutions LLC based in the UAE by subscribing to Optionally Convertible Debentures to support its business operations.
Read Full StoryGOCL Corporation Signs Strategic Multi-Year MoU with Blaze Automation to Enhance Electronics Manufacturing and Product Development
GOCL Corporation Limited has entered a strategic multi-year Memorandum of Understanding with Blaze Automation Services Pvt. Ltd to collaboratively develop products and scale electronic manufacturing for diverse sectors including industrial, automotive, defence, and e-mobility.
Read Full StoryMax Estates Unveils The Bungalows, a ₹4,000 Crore Luxury Residential Project in Gurugram with Privacy-Focused Design
Max Estates Limited has launched The Bungalows, a premium residential project in Gurugram's Sector 59, offering 243 meticulously designed 4-bedroom homes, townhouses, and penthouses. The project is executed in phases with an estimated Gross Development Value of ₹4,000 crore and emphasizes privacy, luxury architecture, and sustainability.
Read Full Story